IP Library Granted Patent US 10,004,827
Granted Patent B2
US 10,004,827 · App. 14/182,791 · Granted Jun 26, 2018

Extracellular matrix-derived gels and related methods

Inventors: Stephen F. Badylak (Pittsburgh, PA); Donald Freytes (Pittsburgh, PA)
Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
A61L27/3633A61K35/12A61L27/34A61L27/3687A61L27/38A61L27/52A61L27/54C12P21/06A61K38/00A61L2300/64A61L2400/06A61L2420/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,004,827
App. No.
14/182,791
Granted
Jun 26, 2018
Kind
B2
Abstract

Provided are methods for preparing gelled, solubilized extracellular matrix (ECM) compositions useful as cell growth scaffolds. Also provided are compositions prepared according to the methods as well as uses for the compositions. In one embodiment a device, such as a prosthesis, is provided which comprises an inorganic matrix into which the gelled, solubilized ECM is dispersed to facilitate in-growth of cells into the ECM and thus adaptation and/or attachment of the device to a patient.

Claims (32)

1. A composition comprising: (a) lyophilized extracellular matrix derived from a mammalian tissue and digested with an acid protease, and (b) the acid protease, wherein the composition after addition of water is a liquid at a temperature of about 4° C. to 25° C. and gels at a temperature greater than 25° C.

2. The composition of claim 1 , wherein the extracellular matrix is comminuted.

3. The composition of claim 1 , wherein the mammalian tissue comprises cardiac tissue.

4. The composition of claim 1 , wherein the composition has a pH between 7.2 and 7.8.

5. The composition of claim 1 , wherein the protease is pepsin.

6. The composition of claim 1 , wherein the composition is injectable through a needle.

7. The composition of claim 1 , wherein the composition is chemically cross-linked.

8. The composition of claim 1 , wherein the extracellular matrix comprises collagen and glycosaminoglycan.

9. The composition of claim 1 , wherein the composition further comprises a biocompatible material, a cell, a drug, a growth factor or an antibiotic.

10. The composition of claim 1 , wherein the extracellular matrix is a non-dialyzed extracellular matrix.

11. The composition of claim 1 , wherein the composition is a liquid.

12. The composition of claim 11 , wherein the composition transitions to a gel form at a physiological temperature.

13. The composition of claim 11 , wherein the extracellular matrix is suspended in the liquid.

14. The composition of claim 11 , wherein the extracellular matrix is solubilized in the liquid.

15. A composition comprising: (a) extracellular matrix derived from a mammalian tissue and digested with an acid protease, and (b) the acid protease, wherein the composition is chemically crosslinked.

16. A method for correcting a disease-induced tissue defect in a subject in need of repair or augmentation of said tissue defect comprising administering to said subject an effective amount of a composition comprising:

(a) lyophilized extracellular matrix derived from a mammalian tissue and digested with an acid protease, and

(b) the acid protease,

wherein the composition after addition of water is a liquid at a temperature of about 4° C. to 25° C. and gels at a temperature greater than 25° C.

17. The method of claim 16 , wherein the extracellular matrix is comminuted.

18. The method of claim 16 , wherein the mammalian tissue comprises cardiac tissue.

19. The method of claim 16 , wherein the composition has a pH between 7.2 and 7.8.

20. The method of claim 16 , wherein the protease is pepsin.

21. The method of claim 16 , wherein the composition is injectable through a needle.

22. The method of claim 16 , wherein the composition is chemically cross-linked.

23. The method of claim 16 , wherein the extracellular matrix comprises collagen and glycosaminoglycan.

24. The method of claim 16 , wherein the composition further comprises a biocompatible material, a cell, a drug, a growth factor or an antibiotic.

25. The method of claim 16 , wherein the extracellular matrix is a non-dialyzed extracellular matrix.

26. The method of claim 16 , wherein the composition is a liquid.

27. The method of claim 26 , wherein the composition transitions to a gel form at a physiological temperature.

28. The method of claim 26 , wherein the extracellular matrix is suspended in the liquid.

29. The method of claim 26 , wherein the extracellular matrix is solubilized in the liquid.

Assignments (2)
CONFIRMATORY LICENSE Recorded Apr 7, 2015
From: UNIVERSITY OF PITTSBURGH
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 035378/0582 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 14, 2014
From: BADYLAK, STEPHEN F.; FREYTES, DONALD
To: UNIVERSITY OF PITTSBURGH ? OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
Reel/Frame 032888/0422 →
Continuity (4)
Division 13684830 · Nov 26, 2012
Continuation 12040140 · Feb 29, 2008
Provisional Application 60892699 · Mar 2, 2007
Related Publication 20140219963A1 · Aug 7, 2014
Cited By (6)
US 12,263,270 US 12,303,533 US 12,383,243 US 12,605,489 US 12,653,926 US 12,734,274